Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors
- Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Foley, K. A.; Wang, P. F.; Barber, B. L.; Long, S. R.; Bagalman, J. E.; Wagner, V.; Song, X.; Zhao, Z. // Annals of Oncology;Jul2010, Vol. 21 Issue 7, p1455
Background: Systemic agents in cancer treatment were often associated with possible infusion reactions (IRs). This study estimated the incidence of IRs requiring medical intervention and assessed the clinical and economic impacts of IRs in patients with colorectal cancer (CRC) treated with...
- Prevention means screening for colorectal cancer. Pratt, Timothy // West County Journal;3/14/2012, Vol. 48 Issue 11, pB2
The article suggests that colorectal cancer can be prevented by early screening, based on results of the National Polyp Study.
- Lost PTEN expression linked to EGFR inhibitor resistance in colorectal metastases. // Hem/Onc Today;5/25/2009, Vol. 10 Issue 10, p34
The article discusses research on the relationship between loss of PTEN expression and epithelial growth factor receptor (EGFR) inhibitor resistance in colorectal metastases, conducted by F. Loupakis, published in a 2009 issue of the "Journal of Clinical Oncology."
- Dual-specificity phosphatases predicted outcome for some colorectal tumors. Harris, Jason // Hem/Onc Today;2/25/2009, Vol. 10 Issue 4, p21
The article discusses a study which determined the use of dual-specificity phosphates as a predictor of survival in patients with metastatic colorectal tumors and mutant KRAS under cetuximab regimen.
- Cetuximab may not be cost-effective for colorectal cancer. // Hem/Onc Today;9/10/2009, Vol. 10 Issue 17, p13
The article presents findings of a study on the cost-effectiveness of using cetuximab for the treatment of metastatic colorectal cancer.
- FDA approves genetic test for patients with metastatic colorectal cancer. // Hem/Onc Today;8/10/2012, Vol. 13 Issue 15, p13
The article focuses on the first genetic test approved by the U.S. Food and Drug Administration (FDA) which may help some patients diagnosed with colorectal cancer and their physicians in deciding whether cetuximab can be an effective treatment.
- Cetuximab did not improve PFS, OS in combination regimen for metastatic colorectal cancer. Harris, Jason; Southall, Jennifer // Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p17
The article discusses research being conducted on the effectiveness of cetuximab for treating metastatic colorectal cancer, which references a study by Kjell Magne Tveit and colleagues that was presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy from...
- Cetuximab. // Reactions Weekly;1/14/2012, Issue 1384, p18
The article describes a case of skin ulcerations that developed in an 82-year-old woman while receiving cetuximab for metastatic colorectal cancer.
- Cetuximab with FOLFOX6, FOLFIRI demonstrated high response rates in colorectal cancer with inoperable liver metastases. // Hem/Onc Today;12/25/2009, Vol. 10 Issue 24, p44
The article discusses research being done on the effectiveness of adding cetuximab to neoadjuvant chemotherapy with FOLFOX6 or FOLFIRI for treating colorectal liver metastases, which references a study by G. Folprecht published in a 2009 issue of the journal "Lancet Oncology."